Silence Therapeutics Share Discussion Threads

[1gw] 21/6/2021 16:06

Pretty impressive deal just announced by ARWR for a previously unannounced discovery-stage asset. Let's hope SLN can do something similar with one or more of its multiple undisclosed programs.

[kreature] 15/6/2021 15:02

the 40p forecast

[wilko14] 15/6/2021 10:36

Welcome Back K, share price usually a rises when you start posting so I’m happy to see you.

[1gw] 15/6/2021 09:23

Which forecast is that k?

[kreature] 15/6/2021 08:54

Assuming there’s nothing from Takade, is it best to adjust the forecast here? ( in the obvious direction)

[1gw] 15/6/2021 07:06

No AGM statement then, at least so far. Still waiting on that Takeda negotiation.

[wilko14] 11/6/2021 15:37

Yes interesting theory I have seen suggests VRTX may try to buy DRNA as the cheaper option and then partner the AAT drug ARWR has. Just conjecture but certainly interesting and would pave the way for dominance in that particular market. Any buyouts or even offers would be good news for SLN I think as the valuation gap is huge (as indeed are the pipelines but I think SLN isn’t even at fair value for one drug yet).

[1gw] 11/6/2021 15:08

A quiet day over here so far then, but excitement stateside, with ARWR hitting $90 again and DRNA also up around 6%. A good presentation by ARWR CEO at GS yesterday but what seems to have triggered today's move is more VRTX's troubles on AAT - leaving the way clearer for ARWR's candidate and potentially leaving VRTX looking at acquisitions to boost its pipeline.

[1gw] 10/6/2021 14:07

The BP point is interesting. Someone on the $ARWR twitter feed linked this article (originally published in late 2018 and then slightly updated recently) which includes reference to how big pharma largely abandoned RNAi early on.


You'd have to think some of them were ready to get back in given the results ALNY and ARWR are getting. For anyone with a cardiovascular focus, SLN must be tempting given SLN360 is wholly-owned. Astrazeneca and Takeda (and I suppose MNK) have the inside track, but (especially) if the driver is the RNAi platform rather than the particular drug then there should be plenty of other possibilities.

Whether SLN would feel they would get "fair value" selling out at this point though is debateable.

[wilko14] 10/6/2021 13:42

I agree. If SLN were a $3bn company based on LPa I’d be concerned but I think it’s woefully undervalued and will rise with the sector on the back of some key players. Possibly also a sell to BP who wants to get into RNAI lock stock.

[1gw] 10/6/2021 13:04

I doubt SLN360 can overtake AMG890. While that gives the Arrowhead/Amgen drug a timing advantage (if it makes it to market) it also potentially allows SLN to learn from AMG890's results, in particular dosing amount and frequency. There is also the question of whether SLN can avoid (at least until after approval) a big cardiovascular outcomes study, and that also may be influenced by what AMG890 does.

More generally, ARWR has a whole pile of data readouts coming through in the fairly near term (as well as lots of conference presentations) and that may influence how the market sees (and values) RNAi as a sector.

[wilko14] 10/6/2021 09:28

There’s a suggestion that Amgen and Arrowhead may have an update on their LPa treatment today at the Goldman Sachs conference in the US. I wonder what implications for SLN as Olpasiran would be a direct competitor.

[1gw] 09/6/2021 16:49

Nice UT to get a 648p close in the books on a very quiet day.

[1gw] 09/6/2021 10:06

Feels like it's a bit of a "shot to nothing" at the moment. A few months probably before the next clinical data and when we get near that the nerve-wracking double-sided risk (positive or disappointing results) but in the meantime the chance of them landing a Takeda deal, which ought to be positive (not fully priced in).

Next scheduled "event" (other than the SLN124 pre-clinical posters this week) is the AGM on 15th June - might they announce Takeda then?

[wilko14] 09/6/2021 08:51

Very quiet on here. share price holding up well, seems a decent base established. Also seems to move up when there is liquidity. Arrowhead making some gains in the US on the back of the Biogen FDA approval this week. RNAI could follow with quicker approval times. Hopefully see some decent data from 360 soon and this would be ripe for a purchase.

[wilko14] 28/5/2021 19:21

Yeah I’ve been seeing tons of generic posts pumping that crypto

[1gw] 28/5/2021 19:13

Perhaps someone bought it by mistake and then dumped it once they realised the mistake? There's a post on twitter $sln suggesting that I think - some confusion with this SLN cryptocurrency or whatever it is.

[wilko14] 28/5/2021 19:08

Strange. More volume than I’ve ever seen in the US too. Perhaps something to do with big spreads in that market as there isn’t much liquidity?

[1gw] 28/5/2021 18:39

Wow! What happened there then? We appear to have spiked to $35 (over £8/share equivalent) in the US before collapsing back to around $24 (under £6/share equivalent).

[vonmoger] 27/5/2021 21:29

K, that will be in a few years as far as I can tell... do you think its something the short interest should be concerned about?

[kreature] 27/5/2021 20:12

has 124 completed phase 3 yet?

[1gw] 27/5/2021 16:37

That's a very large UT to drag the price back below 650.

[1gw] 25/5/2021 13:34

I'm hoping they sell a stake to Takeda pretty soon! That's the one "known unknown" that's still out there for this half I think. We've done the first clinical results, we've done the receipt of the $40m from AZN, so it's just the attempt to convert the Takeda technology evaluation deal to a "License Agreement", as specified in the original 7th January 2020 Takeda announcement.

Or as I heard Mark Rothera say at the Chardan presentation in early October:

"We are encouraged by this collaboration and hope it will then transform into a bigger and longer-term deal on numerous fronts"

which seems like it might stretch to equity investment, in the same way as the MNK and AZN deals.

[wilko14] 25/5/2021 08:14

Same here, have accumulated over the years in this and ARWR. Love the potential here. Looks like a classic RG play, a stake will be sold to a bigger pharma at some point imho.

[ayl30] 25/5/2021 07:54

Nice news today. Been here a while, share is one of my buy and forget type sleepers in a pharma p/f. Looks a solid hold with a 3 year view